AUTOLUS THERAPEUTICS PLC (AUTL) Stock News

USA - NASDAQ:AUTL - US05280R1005 - ADR

1.27 USD

-0.02 (-1.55%)

Last: 11/19/2025, 2:58:28 PM

1.32 USD

+0.05 (+3.94%)

Pre-Market: 11/20/2025, 8:24:50 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AUTL Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

7 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

8 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

8 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

9 days ago - By: Benzinga

A Look at Autolus Therapeutics's Upcoming Earnings Report

5 months ago - By: Benzinga

What 4 Analyst Ratings Have To Say About Autolus Therapeutics

10 days ago - By: Zacks Investment Research - Mentions: ASND IMRX ANRO

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

17 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

17 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

21 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

24 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

24 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

2 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

3 months ago - By: Yahoo Finance

Autolus Therapeutics sees cash runway to launch, commercialization of obe-cel

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Yahoo Finance - Mentions: ELTX

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Upcoming Investor Conferences

6 months ago - By: Stocktwits - Mentions: SBIO KOMP

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens